Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabazitaxel nanosomal - Intas Pharmaceuticals/Jina Pharmaceuticals

Next Previous
Search
Drug Profile

Cabazitaxel nanosomal - Intas Pharmaceuticals/Jina Pharmaceuticals

Alternative Names: Cabazitaxel lipid suspension

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Class Amines; Antineoplastics; Benzene derivatives; Esters; Small molecules; Taxanes
  • Mechanism of Action Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 25 Mar 2025 Jina Pharmaceuticals plans a phase II trial for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) (PO, Tablet) in May 2025 (NCT06890832)
  • 28 May 2022 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in India (IV, Suspension)
  • 12 May 2020 Phase-I development is ongoing for Cancer (Second-line therapy or greater, Late-stage disease) in India (IV, Suspension) (Jina Pharmaceuticals pipeline, May 2020)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top